Irbepex-H Tablet contains a combination of Irbesartan 150 mg and Hydrochlorothiazide 12.5 mg, formulated for the management of hypertension. Irbesartan is an angiotensin II receptor antagonist that selectively blocks the binding of angiotensin II to the AT1 receptor, thereby inhibiting vasoconstriction and aldosterone secretion, resulting in vasodilation and reduced blood pressure. Hydrochlorothiazide is a thiazide diuretic that promotes the excretion of sodium and water by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, further aiding in blood pressure reduction. The synergistic effect of these two agents provides effective and sustained antihypertensive control, reducing the risk of cardiovascular events such as stroke and myocardial infarction. Irbepex-H is indicated for patients whose blood pressure is not adequately controlled with monotherapy. It is essential to monitor renal function, electrolyte levels, and blood pressure regularly during treatment. Caution is advised in patients with renal or hepatic impairment, electrolyte imbalances, or a history of hypersensitivity to sulfonamides. Irbepex-H should be used under medical supervision, with dosage adjustments based on therapeutic response and tolerability. This combination therapy offers a convenient once-daily dosing regimen to improve patient compliance in hypertension management.